Ohana Health Plan, a key provider of government-sponsored managed care services in Hawai‘i, in collaboration with the Centene Foundation—the charitable division of Centene Corporation —has launched a state-of-the-art mobile health clinic alongside Hawai‘i Island Community Health Center (HICHC). HICHC is a nonprofit healthcare provider committed to promoting lifelong wellness through […]
Featured News
Meet L•AI•C: Life Time’s AI Revolution in Health and Fitness
Not sure how to structure today’s upper body session or wondering which supplements align with your goals? Life Time’s AI-powered companion for a healthy lifestyle, L•AI•C (pronounced “lay-see”), is now accessible to all users through the free Life Time app. Designed to deliver instant, science-based advice across fitness, nutrition, recovery, […]
From Lab to Clinic: Kinvard Bio Accelerates Antibiotic Pipeline with CARB-X Support
Kinvard Bio Inc., a biotechnology firm at the forefront of developing a new generation of broad-spectrum antibiotics, has announced the receipt of US $2.7 million in follow-on non-dilutive funding from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator). This global non-profit initiative supports the acceleration of antibacterial innovation with the goal of […]
Akeso’s Ivonescimab Moves Closer to Approval with Third sNDA Acceptance in China
Akeso, Inc. has officially announced that the National Medical Products Administration (NMPA) in China has accepted its supplementary New Drug Application (sNDA) for ivonescimab, a PD-1/VEGF bispecific antibody. The application seeks approval for ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). […]
CD40/CD40L Inhibitors: Unlocking the Future of Autoimmune and Transplant Therapies
DelveInsight’s comprehensive analysis of the CD40/CD40L inhibitors market delivers a detailed understanding of current treatment trends, the scope of the target population, and an evaluation of the competitive landscape with a forecast extending to 2034. The report places emphasis on indications where CD40/CD40L inhibitors hold potential, including systemic lupus erythematosus […]
Matrix Deepens Commitment to In-Home Care with New Diagnostic Partner
Matrix Medical Network, a recognized leader in delivering high-quality, home-based healthcare services, has announced a strategic partnership with Molecular Testing Labs (MTL), a CLIA- and New York State-certified, CAP-accredited laboratory known for its innovation and excellence in molecular diagnostics. This collaboration marks a significant step forward in Matrix’s ongoing commitment […]
Revolutionizing Melanoma Care: SkylineDx’s CP-GEP Test Minimizes Surgical Risks
SkylineDx, a leading diagnostics innovator specializing in molecular diagnostics for oncology, inflammatory, and infectious diseases, has announced significant findings from a Danish validation study recently published in the Journal of Surgical Oncology. This study confirms that SkylineDx’s Merlin Assay, also known as CP-GEP, can accurately identify cutaneous melanoma patients, particularly […]
Texas Cardiac Arrhythmia Institute First in U.S. to Implant Leadless Heart Failure Therapy Device
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center electrophysiologists have achieved a significant milestone by being the first medical team in the US to implant a novel, FDA-approved leadless device intended to provide cardiac resynchronization therapy to patients with heart failure. This therapy plays a vital role […]
Saluda Medical Rolls Out EVA Nationwide: A Breakthrough in Spinal Cord Stimulation Treatment
Saluda Medical, Inc., a leader in the advancement of neuromodulation technologies aimed at improving the lives of patients with chronic neurological disorders, has formally declared EVA’s full-scale commercial availability, its most recent advancements in sensing technology, all around the United States. This comes after EVA was approved by the US […]
FDA Grants Orphan Drug Designation to Amphix Bio’s Spinal Cord Injury Treatment
Amphix Bio, an innovative pre-clinical stage biotechnology company, has announced that its lead therapeutic candidate, AMFX-200, has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of acute spinal cord injury (SCI). This condition, which affects approximately 18,000 individuals annually in the United States, often […]
